Not provided
Not provided
Not provided
Not provided
The sponsor is focusing on prospective randomized studies
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this retrospective, open-label, post-market study is to evaluate the safety and efficacy of Transoral Incisionless Fundoplication (TIF) performed with EsophyX (brand name) in a broad range of GastroEsophageal Reflux Disease (GERD) patients treated at high volume centers across the United States.
This retrospective, open-label, post-market study evaluates the safety and efficacy of Transoral Incisionless Fundoplication (TIF) performed with EsophyX (brand name) in a broad range of GastroEsophageal Reflux Disease (GERD) patients treated at high volume centers across the United States, in clinical routine practice, as standard of care.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Transoral Incisionless Fundoplication | Experimental | Intervention: Transoral Incisionless Fundoplication 2.0 technique iteration (TIF 2.0). With patient in general anesthesia. The EsophyX (brand name) device is introduced through the mouth, over a standard endoscope, into the stomach. Multiple gastro-esophageal plications are performed, apposing the fundus to the distal part of the esophagus and repositioning the GastroEsophageal Junction (GEJ) below the diaphragm, into the abdomen. Multiple prolene fasteners are used to secure and keep in place the plications. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Transoral Incisionless Fundoplication | Device | Transoral incisionless esophago-gastric fundoplication performed using the EsophyX (brand name) system with SerosaFuse (brand name) fasteners (EndoGastric Solutions, Inc., Redmond, Washington, USA) and following the standardized Transoral Incisionless Fundoplication 2.0 technique iteration (TIF2.0) protocol. |
| Measure | Description | Time Frame |
|---|---|---|
| Typical and Atypical Gastroesophageal Reflux Disease (GERD) Symptom Elimination | Typical and atypical GERD symptom elimination in GERD Health-Related Quality of Life (GERD-HRQL). HRQL questionnaire measures typical GERD symptoms, scale 0-5 for each of 9 questions; scores considered normalized if every score is 0), GERD Symptom Score (GERSS measures atypical GERD symptoms, scale 0-3 for severity and 0-4 for frequency, with total scale 0-60; patients with controlled reflux symptoms are expected to have a score of <18) and Reflux Symptom Index (RSI measures atypical laryngopharyngeal (LPR) symptoms, scale 0-5 for each of 9 questions with maximum of 45 with a normality threshold of < or = 13) questionnaires) at the follow-up. | median 7 months (range 5-17 months) |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants Experiencing Serious Adverse Events (SAEs) & Unanticipated Adverse Device Effects (UADEs) | The treatment will be considered safe if the incidence of serious adverse events (SAEs) is below the ranges reported for laparoscopic fundoplication. | median 7 months (range 5-17 months) |
| Number of Participants Reporting Complete Elimination of Proton Pump Inhibitor (PPI) Use |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| William Barnes, MD MBA FACS | Livingston Hospital and Healthcare Services Inc, CAH | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Munroe Regional Medical Center | Ocala | Florida | 34471 | United States | ||
| Livingston Hospital and Healthcare Services, Inc. CAH |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
124 patients were eligible to participate in the study, but 110 signed consent and started the study. Of the 14 that didn't start, 13 could not be reached at start of study and one patient did not receive the TIF procedure due to intraoperative hematoma.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Transoral Incisionless Fundoplication | Intervention: Transoral Incisionless Fundoplication 2.0 technique iteration (TIF 2.0). With patient in general anesthesia. The EsophyX (brand name) device is introduced through the mouth, over a standard endoscope, into the stomach. Multiple gastro-esophageal plications are performed, apposing the fundus to the distal part of the esophagus and repositioning the Gastroesophageal Junction (GEJ) below the diaphragm, into the abdomen. Multiple prolene fasteners are used to secure and keep in place the plications. Transoral Incisionless Fundoplication: Transoral incisionless esophago-gastric fundoplication performed using the EsophyX (brand name) system with SerosaFuse (brand name) fasteners (EndoGastric Solutions, Inc., Redmond, Washington, USA) and following the standardized transoral incisionless fundoplication 2.0 technique iteration (TIF2.0) protocol. |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Baseline population is 110 of 124 who were eligible. 110 signed informed consent to participate in the study.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Transoral Incisionless Fundoplication | Intervention: Transoral Incisionless Fundoplication: TIF 2.0 technique iteration. With patient in general anesthesia. The EsophyX device is introduced through the mouth, over a standard endoscope, into the stomach. Multiple gastro -esophageal plications are performed, apposing the fundus to the distal part of the esophagus and repositioning the GEJ below the diaphragm, into the abdomen. Multiple prolene fasteners are used to secure and keep in place the plications. Transoral Incisionless Fundoplication: Transoral incisionless esophago-gastric fundoplication performed using the EsophyX (brand name) system with SerosaFuse (brand name) prolene fasteners (EndoGastric Solutions, Inc., Redmond, Washington, USA) and following the standardized TIF2.0 protocol. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Median |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Typical and Atypical Gastroesophageal Reflux Disease (GERD) Symptom Elimination | Typical and atypical GERD symptom elimination in GERD Health-Related Quality of Life (GERD-HRQL). HRQL questionnaire measures typical GERD symptoms, scale 0-5 for each of 9 questions; scores considered normalized if every score is 0), GERD Symptom Score (GERSS measures atypical GERD symptoms, scale 0-3 for severity and 0-4 for frequency, with total scale 0-60; patients with controlled reflux symptoms are expected to have a score of <18) and Reflux Symptom Index (RSI measures atypical laryngopharyngeal (LPR) symptoms, scale 0-5 for each of 9 questions with maximum of 45 with a normality threshold of < or = 13) questionnaires) at the follow-up. | Posted | Count of Participants | Participants | median 7 months (range 5-17 months) |
|
This is a retrospective study. TIF procedures were performed from November 2008 through December 2009. The study enrolled patients and collected post-TIF follow up visits in 2010. Adverse event data was collected from day of TIF procedure through final follow-up visit.
There was an intra-op event described in the study publication, but because the TIF procedure could not be completed due to an intra-op hematoma, patient did not sign consent or start this retrospective study. This is not included as a study-related adverse event.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Transoral Incisionless Fundoplication | Intervention: Transoral Incisionless Fundoplication 2.0 technique iteration (TIF 2.0). With patient in general anesthesia. The EsophyX (brand name) device is introduced through the mouth, over a standard endoscope, into the stomach. Multiple gastro-esophageal plications are performed, apposing the fundus to the distal part of the esophagus and repositioning the GEJ below the diaphragm, into the abdomen. Multiple prolene fasteners are used to secure and keep in place the plications. Transoral Incisionless Fundoplication: Transoral incisionless esophago-gastric fundoplication performed using the EsophyX (brand name) system with SerosaFuse (brand name) fasteners (EndoGastric Solutions, Inc., Redmond, Washington, USA) and following the standardized TIF2.0 protocol. |
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Adrian Lobontiu, Chief Medical Officer | EndoGastric Solutions | 1 650-474-9259 | alobontiu@endogastricsolutions.com |
Not provided
| ID | Term |
|---|---|
| D005764 | Gastroesophageal Reflux |
| D006356 | Heartburn |
| D006685 | Hoarseness |
| D003371 | Cough |
| ID | Term |
|---|---|
| D015154 | Esophageal Motility Disorders |
| D003680 | Deglutition Disorders |
| D004935 | Esophageal Diseases |
| D005767 | Gastrointestinal Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
|
Patients reporting complete discontinuation of daily PPI use will be considered clinically significant. |
| median 7 months (range 5-17 months) |
| Number of Participants With Healing of Reflux Esophagitis | One LA grade reduction will be considered clinically significant. LA grades are A, B, C, D, with A being the least severe esophagitis. No grade assigned is considered "normal", i.e. no esophagitis reported. | median 7 months (range 5-17 months) |
| Number of Participants Whose Baseline Hiatal Hernia Has Remained Reduced at Post-TIF Follow-up | Measurement obtained by study investigator, under endoscopic visualization using cm markings on the endoscope. Outcome measure assesses if hiatal hernia that was present at baseline and reduced (size reduction to < 1 cm is considered clinically significant) during TIF procedure, has remained reduced at the post-TIF follow up exam. | median 7 months (range 5-17 months) |
| Number of Participants With Normalization or Clinically Significant Improvement in Esophageal Acid Exposure Assessed by Impedance/pH Testing and Reflux Episodes | Esophageal acid exposure will be measured objectively by 48-hour Bravo Potential of Hydrogen (pH) or 24-hour impedance/pH testing at the follow-up (where pH testing is available). Normalization of esophageal acid exposure will be defined by total time pH< 4 for ≤ 6% of 24-hour or for ≤ 5.3% of 48-hour monitoring period. The number of reflux episodes of ≤ 44 per each 24-hour period will be considered normal. | median 7 months (range 5-17 months) |
| Salem |
| Kentucky |
| 42078 |
| United States |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Region of Enrollment | 64 patients from Livingston Hospital and Healthcare Services in Salem, Kentucky, and 60 from Munroe Regional Medical Center in Ocala, Florida were eligible to participate in the study but 110 signed consent and started. 13 eligible patients were lost to follow up at start of study, and one did not have Transoral Incisionless Fundoplication (TIF) completed due to intraoperative hematoma. | Number | participants |
|
| Body Mass Index (BMI) > or equal to 35 | Count of Participants | Participants |
|
| Gastroesophageal Reflux disease (GERD) symptom duration (years) | median number of years of GERD symptom duration is 9 years | Count of Participants | Participants |
|
| Proton Pump Inhibitor (PPI) therapy duration (years) | median number of years of PPI duration therapy is 8 years | Count of Participants | Participants |
|
| Hiatal hernia size | This is a subjective measure made by the study investigator using endoscopic visualization of the gastroesophageal junction. Normal or small hiatal hernia is <= 1cm. Hill Grade system is used: Hill I, II, III, IV, with Hill I normal hiatus and Hill IV large, loose hiatal opening. Hill IV is an exclusion for this study. Hill II may indicate a 2cm hiatal hernia, Hill III a 3cm hiatal hernia for example. | 70 of 110 participants had a 2 or 3cm hiatal hernia at baseline | Count of Participants | Participants |
|
| Esophagitis using Los Angeles (LA) grading | LA grading of esophagitis is an A, B, C, D system, where A is the least severe esophagitis and D is the most severe. LA grade D is an exclusion for this protocol. Normal or no esophagitis reported, will have no grade listed. LA grading is a subjective measure made using an endoscope to visualize the gastroesophageal junction to assess for esophagitis based on the LA grade criteria. An improvement of one grade post-TIF is considered a success, e.g., from grade B to grade A, or grade A to no grade (normal), etc. | 64 of 110 participants had esophagitis at baseline | Count of Participants | Participants |
|
|
|
| Secondary | Number of Participants Experiencing Serious Adverse Events (SAEs) & Unanticipated Adverse Device Effects (UADEs) | The treatment will be considered safe if the incidence of serious adverse events (SAEs) is below the ranges reported for laparoscopic fundoplication. | There were no serious adverse events or UADE during the study. | Posted | Count of Participants | Participants | median 7 months (range 5-17 months) |
|
|
|
| Secondary | Number of Participants Reporting Complete Elimination of Proton Pump Inhibitor (PPI) Use | Patients reporting complete discontinuation of daily PPI use will be considered clinically significant. | Posted | Count of Participants | Participants | median 7 months (range 5-17 months) |
|
|
|
| Secondary | Number of Participants With Healing of Reflux Esophagitis | One LA grade reduction will be considered clinically significant. LA grades are A, B, C, D, with A being the least severe esophagitis. No grade assigned is considered "normal", i.e. no esophagitis reported. | Of 53 patients examined at follow up for esophagitis or hiatal hernia status, 30 had reported esophagitis at baseline. Please note: there was 1 new case of esophagitis reported at follow-up, that had not been present at baseline. | Posted | Count of Participants | Participants | median 7 months (range 5-17 months) |
|
|
|
| Secondary | Number of Participants Whose Baseline Hiatal Hernia Has Remained Reduced at Post-TIF Follow-up | Measurement obtained by study investigator, under endoscopic visualization using cm markings on the endoscope. Outcome measure assesses if hiatal hernia that was present at baseline and reduced (size reduction to < 1 cm is considered clinically significant) during TIF procedure, has remained reduced at the post-TIF follow up exam. | 53 patients were assessed for esophagitis and presence of hiatal hernia at follow-up. Hiatal hernia was present at baseline and reduced during TIF procedure in 34 of the patients examined at follow-up. Hiatal hernia in 33 of 34 remained reduced at follow-up. Please note: there was one new case of hiatal hernia reported that had not been present at baseline. | Posted | Count of Participants | Participants | median 7 months (range 5-17 months) |
|
|
|
| Secondary | Number of Participants With Normalization or Clinically Significant Improvement in Esophageal Acid Exposure Assessed by Impedance/pH Testing and Reflux Episodes | Esophageal acid exposure will be measured objectively by 48-hour Bravo Potential of Hydrogen (pH) or 24-hour impedance/pH testing at the follow-up (where pH testing is available). Normalization of esophageal acid exposure will be defined by total time pH< 4 for ≤ 6% of 24-hour or for ≤ 5.3% of 48-hour monitoring period. The number of reflux episodes of ≤ 44 per each 24-hour period will be considered normal. | Note: neither 48-hour Bravo pH nor 24-hour impedance/pH testing was completed. pH testing was unavailable at the study sites. Study protocol noted that testing would be completed "if available". In the absence of these testing tools, sites relied on detailed history, physical signs, symptom evaluation, barium swallow, and repeated esophagogastroduodenoscopy (EGD) with biopsy to make diagnosis. This continues to be the most commonly used method of GERD diagnosis among community physicians. | Posted | median 7 months (range 5-17 months) |
|
|
| 0 |
| 110 |
| 0 |
| 110 |
| 0 |
| 110 |
Not provided
Not provided
| D004066 | Digestive System Diseases |
| D012817 | Signs and Symptoms, Digestive |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D014832 | Voice Disorders |
| D007818 | Laryngeal Diseases |
| D012140 | Respiratory Tract Diseases |
| D012120 | Respiration Disorders |
| D010038 | Otorhinolaryngologic Diseases |
| D009461 | Neurologic Manifestations |
| D009422 | Nervous System Diseases |
| D012818 | Signs and Symptoms, Respiratory |